Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Added

TDQS

A4.8/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly, idempotent, and non-destructive behavior. The description adds substantial context: type-specific data sources (SEC EDGAR/XBRL, FAERS), fiscal-year handling, result sorting by primary metric, and return format with citation URIs. This goes well beyond annotations and clearly sets behavioral expectations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is longer than the calibrated high example but remains front-loaded with trigger phrases and key guidance. Every sentence adds value, though the 'Replaces 8–15 sequential lookups' clause is somewhat redundant with the ALWAYS PREFER statement. It is dense but not padded.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description properly explains return values (paired data + citation URIs) and sorting behavior. It covers both entity types, data sources, and edge cases like off-calendar fiscal years, making it complete for a tool of moderate complexity.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 100%, so the schema already documents type and values. The description adds meaningful beyond-schema details such as the 2–5 range, example tickers/drug names, and the fact that results are sorted by primary metric, which helps interpret values. However, it does not add much about parameter syntax beyond examples.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description explicitly states the tool performs side-by-side comparisons of 2–5 companies or drugs in one call, using clear trigger phrases like 'X vs Y' and 'which is bigger.' It distinguishes itself from sequential single-entity lookups and sibling tools like entity_profile by focusing on multi-entity comparison.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit when-to-use guidance with example queries and an 'ALWAYS PREFER' directive over sequential single-pack lookups. It also clarifies type-specific usage for company vs drug, but does not name specific alternative tools, which is a minor gap.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.8/5.0
Disambiguation2/5

Several tools route the same style of query to the same Pipeworx catalog: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, discover_tools, and suggest_questions all overlap in purpose, and ask_pipeworx_beta is explicitly identical to ask_pipeworx. The prediction-market tools also blur together, with bet_research, polymarket_arbitrage, polymarket_edges, polymarket_edge_tracker, and polymarket_fill_risk all covering overlapping analysis territory.

Naming Consistency3/5

The tools are consistently lowercase snake_case, but the naming convention is mixed: some are verb_noun (predict_gender, generate_llms_txt), some are noun phrases (entity_profile, recent_alerts), some are bare verbs (remember, forget), and many share domain prefixes like ask_pipeworx or polymarket_. It is readable, but there is no single predictable pattern across the set.

Tool Count2/5

At 33 tools, this exceeds the 25+ threshold where the surface becomes hard to navigate. More importantly, the count does not match the server's apparent genderize identity: the vast majority of tools are unrelated Pipeworx research, prediction-market, memory, and subscription utilities bolted onto a two-tool gender-prediction core.

Completeness3/5

As a broad research assistant, the set is substantial: it covers question routing, grounded verification, deep research, entity profiles, comparisons, change feeds, memory, and subscriptions. However, the actual genderize domain is thin—just two prediction tools with no batch, supported-country, or accuracy endpoints—and several unrelated capabilities feel bolted on, making coverage uneven.